Phase 2 N=100 Camostat Mesilate Treating Patients With Hospitalized Patients With COVID-19
Severe Acute Respiratory Syndrome
Primary: Proportion of Patients Alive and Free From Respiratory Failure — .891; .884 Proportion of patients
Clinical Trial Search
Completed trials with posted results — search by concept, filter by the parameters that matter at the bedside.
Phase 2 N=39 A Phase I/II Study of Nivolumab, Ipilimumab and Plinabulin in Patients With Recurrent Small Cell Lung Cancer
Lung Cancer · SCLC
Primary: Phase I: Maximum Tolerated Dose (MTD) — 30 mg/m^2
Phase 2 N=852 Study of a Pneumococcal Conjugate Vaccine When Administered Concomitantly With Routine Pediatric Vaccines in Healthy Toddlers and Infants
Pneumococcal Immunisation · Diphtheria Immunisation · Tetanus Immunisation
Primary: Number of Participants With Immediate Adverse Events (AEs) — 0; 0; 0; 0 Participants
Phase 2 N=51 A Study to Investigate the Effect of MEDI0382 on Hepatic Glycogen Metabolism in Overweight and Obese Subjects With Type 2 Diabetes Mellitus.
Type 2 Diabetes Mellitus
Primary: Change in Hepatic Glycogen Concentration Adjusted for Liver Volume as Measured by MRS at T = 4 Hours Post Standardised Morning Meal From Baseline (Day -1) to the End of…
Phase 2 N=51 A Study to Evaluate ONM100, an Intraoperative Fluor Imaging Agent for the Detection of Peri Mets
Peritoneal Carcinomatosis
Primary: Percentage of Patients That Had at Least One Additional Lesion Detected Under Pegsitacianine Guidance Following CRS That Was Confirmed as Positive for Disease by…
Phase 2 N=153 Small Cell Lung Carcinoma Trial With Nivolumab and IpiliMUmab in LImited Disease
Limited Stage Small Cell Lung Cancer · Small Cell Lung Cancer
Primary: Progression-free Survival (PFS) — 14.5; 10.7 months
Phase 2 N=20 A Study to Evaluate Pegsitacianine, an Intraoperative Fluorescence Imaging Agent for the Detection of Lung Malignancies
Lung Cancer
Primary: Proportion of Patients Experiencing at Least One Clinically Significant Event (CSE) — 2 Participants
Phase 2 N=45 Study of Pharmacokinetics, Activity and Safety of Ruxolitinib in Pediatric Patients With Grade II-IV Acute Graft vs. Host Disease
Acute Graft Versus Host Disease
Primary: Phase I: Measurement of Pharmacokinetic (PK) Parameter, AUClast, in aGvHD and SR-aGvHD Patients — 252; 372; 154; 239 ng*hr/mL
Phase 2 N=38 Diabetes Homeless Medication Support
Diabetes Mellitus, Type 2 · Housing Problems · Psychological Distress
Primary: Experience During the Intervention — 29.06; 28.22 score on a scale
Phase 2 N=318 A Study to Test Whether Taking BI 1358894 for 8 Weeks Helps Adults With Post-traumatic Stress Disorder
Post-Traumatic Stress Disorder
Primary: Change From Baseline in Clinician-Administered Post Traumatic Stress Disorder (PTSD) Scale for DSM-5 (CAPS-5) Total Severity Score at Week 8 — -17.19; -17.13 units on a…
Phase 2 N=49 Romidepsin in Combination With Lenalidomide in Adults With Relapsed or Refractory Lymphomas and Myeloma
Multiple Myeloma · Non-Hodgkin's Lymphoma
Primary: Number of Dose Limiting Toxicities/DLTs — 0; 1; 0; 1 DLT's
Phase 2 N=41 Clinical Trial Assessing Temelimab Following Rituximab Treatment in Patients With Relapsing Forms of Multiple Sclerosis
Multiple Sclerosis
Primary: Safety and Tolerability — 10; 9; 10; 9 Participants with at least one TEAE
Phase 2 N=17 Investigating the Safety and Efficacy of Rituximab and Pembrolizumab in Relapsed/Refractory Waldenström's Macroglobulinaemia
Waldenstrom Macroglobulinemia
Primary: Percentage of Patients Achieving at Least a Major Response Rate at 24 Weeks Post Commencing Treatment — 8 Participants
Phase 2 N=5 T-Cell Infusion, Aldesleukin, and Utomilumab in Treating Patients With Recurrent Ovarian Cancer
COL6A3 Positive · HLA-A*0201 Positive Cells Present · PRAME Positive
Primary: Assess Safety and Toxicity of Adoptively Transferred Central Memory-type CTL Targeting Ovarian Cancer Antigens Administered Alone, and in Combination With, Utomilumab…
Phase 2 N=72 Onvansertib in Combination With Abiraterone and Prednisone in Adult Patients With Metastatic Castration-Resistant Prostate Cancer
Metastatic Castration-Resistant Prostate Cancer
Primary: Percentage of Participants Achieving Disease Control at or Before 12 Weeks — 13.6; 50.0; 35.0; 35.7 percentage of participants